TYAN
25.2.2020 09:02:14 CET | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, is exhibiting their latest embedded motherboards optimized for the intelligent edge to service a wide range of vertical markets including security, industrial automation, communication and networking at Embedded World 2020 from February 25th ~27th , booth 2-311 in Nuremberg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005008/en/
“Based on the Intel® Xeon® E-2200 processor and 9th Generation Intel® Core™ i3/i5/i7 series processor, TYAN’s embedded motherboards demonstrate how standard-based platforms powered by robust processors efficiently meet the demands of data analytics at the IoT edge," said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. Hsu added, “With key features including compact form factors, a wide range of operating temperatures, and long product supply lifetime, our Tempest EX motherboards are the ideal choice to build up edge systems that can bridge compute, storage, and networking resources.”
TYAN’s embedded products provide 7-year supply lifecycle, wide operating temperature range of 0-55°C and optional EMC Class B certification on selected boards, which are highly required for most embedded IoT applications. The Tempest EX S5550-EX is equipped with up to four 1000Base-T LAN ports, three standard PCIe slots, eight SATA 6G ports, HD audio and display port interfaces in Micro-ATX form factor; the Tempest EX S5552-EX supports four 1000Base-T LAN ports, 8-port SAS 12G controller, four standard PCIe and an optional 32-bit legacy PCI slot in ATX form factor. Both S5550-EX and S5552-EX boards are well suited for industrial automation server applications. The Tempest EX S5555-EX with two display ports, one DVI-D port, and 7.1 channel high definition audio in Micro-ATX form factor is ideal for embedded workstation applications.
The Tempest EX S5557 features two 1000Base-T LAN ports, 12V DC power input and two display ports in Thin Mini-ITX form factor. The ultra-slim embedded motherboard is a perfect fit for IoT appliance deployment. Moreover, the Thunder CX GX38-B5550 is a 1U single-socket Intel Xeon E-2200 processor-based compact server for IoT and edge computing. Featuring up 4 DDR4 DIMM slots, up to 4 onboard GbE LAN ports, 1 PCIe x8 slot and two 3.5" internal SATA 6G drive bays within a 15” deep chassis, Thunder CX GX38-B5550 makes it a top choice for datacenters with space constraints.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005008/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release
Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 08:00:00 CEST | Press release
As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Ga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom